Europe's Cancer Fight at a Crossroads

Cancer continues to be a primary cause of death and disability across Europe, with significant implications for public health and economic growth. The continent is at a pivotal moment as the EU Beating Cancer Plan concludes its initial phase, demanding a strategic investment in cancer care rather than viewing it solely as a cost.

Significant progress has been made, with cancer innovations preventing millions of deaths and generating valuable quality-adjusted life years. However, Europe is hindered by substantial delays in patient access to these advancements. On average, there is a 578-day gap between EU approval and patient access to innovative medicines, a delay that is worsening and undermining Europe's leading position in health innovation.

Europe's competitiveness in biopharmaceutical research and development has declined, with investment per capita in innovative medicines lagging behind other high-income nations. This trend jeopardizes job creation, private investment, and strategic autonomy in a critical sector.

To address these challenges, policymakers are urged to modernize health technology assessment, accelerate access pathways, enhance prevention and screening programs, and increase public funding for innovative medicines. Such smart investments are crucial for improving health outcomes, boosting workforce participation, and fostering sustainable economic growth.

Ultimately, Europe faces a defining choice: to invest proactively in cancer innovation for improved survival rates and economic strength, or to permit delays and underinvestment to widen existing gaps. Aligning policies, funding, and access around innovation presents a powerful opportunity to make health a cornerstone of Europe's future prosperity.